Biopharminternational - biopharminternational.com

General Information:

Latest News:

Development of Robust Charge Heterogeneity Assays using DOE 27 Aug 2013 | 09:00 am

Develop robust charge heterogeneity assays using Design of Experiment (DOE). Utilizing imaged cIEF and DOE provides efficient and rapid method development and reduces assay failure. This application n...

AstraZeneca's MedImmune To Acquire the Biopharmaceutical Company Amplimmune 27 Aug 2013 | 09:00 am

AstraZeneca's MedImmune has agreed to acquire Amplimmune, which specializes in cancer immunology.

Improving Aggregate Removal from Monoclonal Antibody Feed Using High Resolution Cation Exchange Chromatography 27 Aug 2013 | 09:00 am

Nuvia™ HR-S media is a new cation exchanger designed for high resolution of closely related product impurities such as aggregates. It delivers excellent resolution with a final aggregate content of < ...

Cookie Cutter Proteolysis: Achieving Reproducible, Efficient Digestions for Proteomic Workflows 27 Aug 2013 | 09:00 am

Recently, an automated protein digestion platform was developed which accelerates the digestion process while providing exceptional reproducibility. As demonstrated here, it offers complete, reproduci...

Amgen to Acquire Onyx Pharmaceuticals in MultiBillion Deal 26 Aug 2013 | 09:00 am

Amgen acquires Onyx Pharmaceuticals for $125 per share in cash.

Vical Restructure's and Reduce's Staff 26 Aug 2013 | 09:00 am

Vical's restructuring will leave the company with approximately 74 employees.

Shire, and Santaris Extend Alliance to Develop LNA-drugs 26 Aug 2013 | 09:00 am

Santaris Pharma and Shire have extended their partnership in the rare genetic disease space.

ProteinSimple - Development of Robust Charge Heterogeneity Assays using DOE 22 Aug 2013 | 09:00 am

ProteinSimple - Development of Robust Charge Heterogeneity Assays using DOE

BioRad - Improving Aggregate Removal from Monoclonal Antibody Feed Using High Resolution Cation Exchange Chromatography 21 Aug 2013 | 09:00 am

BioRad - Improving Aggregate Removal from Monoclonal Antibody Feed Using High Resolution Cation Exchange Chromatography

Novartis Receives Third FDA Breakthrough Designation 20 Aug 2013 | 09:00 am

FDA has granted Novartis breakthrough therapy designation to BYM338 for sporadic inclusion body myositis.

Recently parsed news:

Recent searches: